Form 4: Guardant Health CCO Reports RSU Vesting & Tax Sale

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported transactions related to his beneficial ownership.
• On December 15, 2025, 1,402 shares of Common Stock were acquired through the vesting of restricted stock units (RSUs).
• Concurrently, 594 shares of Common Stock were disposed of at a price of $102.67 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Freeman beneficially owns 26,795 shares of Common Stock.
• Additionally, Mr. Freeman holds 2,804 derivative securities in the form of Restricted Stock Units.
• The original RSU award was granted on June 9, 2023, vesting over a three-year period, with 33% vesting on June 15, 2024, and the remaining 67% vesting in equal quarterly installments over the subsequent two years.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to executive compensation, which is neutral in sentiment. It reflects the normal course of business for a publicly traded company's compensation structure.

Positives

• The vesting of restricted stock units indicates a component of executive compensation being realized, aligning management's interests with shareholder value over time.
• The transaction is a routine part of executive compensation plans, demonstrating the company's commitment to its long-term incentive programs.

Negatives

• A portion of shares (594 shares) was sold to cover tax withholding obligations, which slightly reduces the direct equity ownership of the Chief Commercial Officer.

Future Outlook

The remaining 67% of the restricted stock unit award, granted on June 9, 2023, is scheduled to vest in equal quarterly installments over the two-year period following June 15, 2024.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies in various industries, including healthcare technology. It does not provide specific insights into broader industry trends or competitive landscape beyond the company's internal compensation practices.

Related Party Transactions

• Vesting of restricted stock units and subsequent sale of shares by Chief Commercial Officer Chris Freeman to cover tax obligations, which is a transaction involving a related party (an executive officer).

Stakeholder Impact

• Shareholders: Minor impact from the routine vesting and tax-related sale, which is a standard part of executive compensation and generally not considered a significant event.
• Employees: Reinforces the company's compensation structure for executives, potentially influencing morale and retention for other employees with similar equity awards.

Next Steps

• Continued vesting of the remaining 67% of the RSU award in equal quarterly installments over the next two years.

Key Dates

Keywords

Guardant Health, GH, Chris Freeman, Chief Commercial Officer, Form 4, SEC filing, Restricted Stock Units, RSU vesting, insider transaction, tax withholding, beneficial ownership